Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00160407
Other study ID # 12458
Secondary ID XEN185
Status Completed
Phase Phase 4
First received September 8, 2005
Last updated November 19, 2007
Start date October 2003
Est. completion date December 2006

Study information

Verified date November 2007
Source St. Louis University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic changes that are typical of NASH.


Description:

Previous studies have suggested that steady weight loss over time will result in improvement in aminotransferases, and more importantly, underlying histopathology in patients with NASH. A total of 50 biopsy-proven NASH patients will be enrolled in a prospective, randomized fashion. Twenty-five patients have been enrolled at the primary study site at Saint Louis University. Recruitment of the next 25 patients is taking place at a study subsite at Brooke Army Medical Center in San Antonio, Texas.

This will be an open-label study comparing an established weight loss program (1400-calorie diet with 30% fat) plus daily vitamin E (800 IU) and a daily multivitamin to the same weight loss program, daily vitamin E (800 IU) and multivitamin, plus orlistat (120 mg), three times daily for 36 weeks.

Data to be collected from prospective patients includes demographic information, such as age, sex, past medical history, medications, height and weight. Biochemical data to be collected from prospective patients includes liver enzymes, measures of insulin resistance to include, insulin levels, lipid panel, hemoglobin A1C, free fatty acids, complete blood count, coagulation studies, and vitamin E levels. Blood will also be collected and stored for markers of inflammation and fibrosis, such as C reactive protein and TNF-alpha. A liver biopsy will be obtained at the completion of the study for both histopathologic analysis and RNA analysis.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Liver biopsy obtained no more than 24 months before randomization with a pathology report confirming that the histological diagnosis is consistent with NASH

- Compensated liver disease with the following laboratory parameters at the entry visit:

- Hemoglobin values of greater than or equal to 12 gm/dl for females or 13 gm/dl for males

- WBC count > 3,000/mm3

- Neutrophil count > 1,500/mm3

- Platelets > 70,000/mm3

- Albumin >3.0 g/dl

- Serum creatinine <1.4mg/dl

- Ability to give informed consent

- Alanine aminotransferase (ALT) greater than or equal to 40 U/L

- BMI > or equal to 27 kg/m2

- Patients who receive orlistat must agree to participate in Xenicare, a free dietary counseling program provided by Roche (sponsor)

Exclusion Criteria:

- Any cause for chronic liver disease other than NASH

- Evidence of decompensated liver disease such as a history of or presence of ascites, bleeding varices, or spontaneous encephalopathy

- History of alcohol consumption of greater than 20 grams per day in the past 2 years

- Prior surgical procedures to include gastroplasty, jejunoileal or jejunocolic bypass

- TPN within the past 6 months

- History of prior organ transplantation

- Concurrent enrollment in other experimental treatment protocols

- Use of ursodeoxycholic acid, rosiglitazone, pioglitazone, or metformin within the 6-month period before enrollment

- Women who are pregnant or breast-feeding

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Orlistat (Xenical)

Behavioral:
1400 kcal diet (30% fat)


Locations

Country Name City State
United States Brooke Army Medical Center San Antonio Texas
United States Saint Louis University St. Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
St. Louis University Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is weight loss leading to improvement in the global necroinflammatory and fibrosis scores on liver biopsies. A change of one point in the necroinflammatory grade or fibrosis stage will be considered statistically significant.
Secondary BMI,ALT,Serum free fatty acids,HOMA-IR (fasting insulin x fasting glucose/22.4)
See also
  Status Clinical Trial Phase
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Completed NCT02565446 - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram N/A
Not yet recruiting NCT01694342 - Telomere Parameters in Patients With Nonalcoholic Fatty Liver N/A
Completed NCT01464801 - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease N/A
Completed NCT01992809 - Omega 3 Supplementation in Fatty Liver Phase 3
Completed NCT00244569 - Development of a Breath Test for Monitoring Patients With Liver Disease Phase 3
Completed NCT00063635 - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Phase 3
Recruiting NCT03972319 - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study Early Phase 1
Completed NCT03141008 - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT05125757 - Lifestyle Modification in Psoriatic Patients With Fatty Liver N/A
Recruiting NCT05370053 - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology N/A
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting NCT02265276 - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Phase 3
Completed NCT02347007 - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3